Article
The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.
Bausch + Lomb voluntarily recalls select enVista IOLs
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Electroretinography reveals limited duration of dexamethasone implant efficacy in DME
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Beyond mentoring: The power of sponsorship and advocacy in ophthalmology
Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa